Add office photos
Employer?
Claim Account for FREE
AstraZeneca
4.1
based on 849 Reviews
Video summary
Company Overview
Company Locations
Working at AstraZeneca
Company Summary
AstraZeneca is a global, science-led biopharmaceutical business. Their innovative medicines are used by millions of patients worldwide.
Overall Rating
4.1/5
based on 849 reviews
5% above
industry average
Highly rated for
Work-life balance, Company culture, Salary
Work Policy
Hybrid
80% employees reported
Monday to Friday
64% employees reported
Flexible timing
75% employees reported
No travel
49% employees reported
View detailed work policy
Top Employees Benefits
Office cab/shuttle
109 employees reported
Free meal
107 employees reported
Health insurance
107 employees reported
Cafeteria
84 employees reported
View all benefits
About AstraZeneca
Founded in1999 (26 yrs old)
India Employee Count501-1k
Global Employee Count50k-1 Lakh
HeadquartersCambridge, Cambridgeshire, United Kingdom (UK)
Office Locations
--
Websiteastrazeneca.com
Primary Industry
Other Industries
Are you managing AstraZeneca's employer brand? To edit company information,
claim this page for free
View in video summary
We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
Managing your company's employer brand?
Claim this Company Page for FREE
AstraZeneca Ratings
based on 849 reviews
Overall Rating
4.1/5
How AmbitionBox ratings work?
5
416
4
259
3
89
2
31
1
54
Category Ratings
4.1
Work-life balance
4.0
Company culture
3.9
Salary
3.8
Job security
3.8
Skill development
3.8
Work satisfaction
3.4
Promotions
AstraZeneca is rated 4.1 out of 5 stars on AmbitionBox, based on 849 company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at AstraZeneca
based on 789 reviews
4.0
Rated by 182 Women
Rated 3.9 for Work-life balance and 3.9 for Salary
4.1
Rated by 607 Men
Rated 4.2 for Work-life balance and 4.0 for Company culture
Work Policy at AstraZeneca
based on 99 reviews in last 6 months
Hybrid
80%
Work from office
20%
AstraZeneca Reviews
Top mentions in AstraZeneca Reviews
+ 5 more
Compare AstraZeneca with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 4.1/5 based on 849 reviews | 4.0/5 based on 1.8k reviews | 4.1/5 based on 3.1k reviews | 3.8/5 based on 1.2k reviews |
Highly Rated for | Work-life balance Company culture Salary | Work-life balance Company culture Skill development | Skill development Work-life balance Salary | Job security |
Critically Rated for | No critically rated category | Promotions | Promotions | Promotions |
Primary Work Policy | Hybrid 80% employees reported | Work from office 56% employees reported | Work from office 51% employees reported | Work from office 87% employees reported |
Rating by Women Employees | 4.0 Good rated by 182 women | 4.0 Good rated by 228 women | 4.1 Good rated by 399 women | 3.9 Good rated by 79 women |
Rating by Men Employees | 4.1 Good rated by 607 men | 4.0 Good rated by 1.5k men | 4.1 Good rated by 2.5k men | 3.8 Good rated by 1.1k men |
Job security | 3.8 Good | 3.4 Average | 3.7 Good | 3.8 Good |
View more
AstraZeneca Salaries
AstraZeneca salaries have received with an average score of 3.9 out of 5 by 849 employees.
Senior Consultant
(378 salaries)
Unlock
₹11.2 L/yr - ₹41.1 L/yr
Territory Business Manager
(231 salaries)
Unlock
₹3.5 L/yr - ₹12 L/yr
Associate Engineer
(193 salaries)
Unlock
₹3.7 L/yr - ₹10 L/yr
Senior Engineer
(168 salaries)
Unlock
₹8.1 L/yr - ₹25 L/yr
Analyst
(126 salaries)
Unlock
₹7 L/yr - ₹26.9 L/yr
Key Account Manager
(121 salaries)
Unlock
₹5.5 L/yr - ₹18.6 L/yr
Software Engineer
(89 salaries)
Unlock
₹6 L/yr - ₹18 L/yr
Clinical Research Associate
(81 salaries)
Unlock
₹2.9 L/yr - ₹9.3 L/yr
Junior Associate
(62 salaries)
Unlock
₹4.4 L/yr - ₹10 L/yr
Junior Engineer
(59 salaries)
Unlock
₹4 L/yr - ₹6 L/yr
AstraZeneca Interview Questions
Interview questions by designation
Top AstraZeneca interview questions and answers
Get interview-ready with top interview questions
AstraZeneca Jobs
Popular Designations AstraZeneca Hires for
Popular Skills AstraZeneca Hires for
Current Openings
AstraZeneca News
View all
This market sell-off is an April Fool's joke on investors, says a veteran strategist predicting a 27% rally by year's end
- Despite a tough first quarter for US stocks, a veteran investment chief predicts a 27% rally by year's end and advises against selling stocks in April.
- James Demmert of Main Street Research believes a market rebound is imminent, citing the strong state of the economy and earnings.
- Investors are urged to focus on the positive catalysts that drove the market to record highs and not get swayed by negative sentiment.
- The market sell-off is attributed to uncertainty and human error in economic prognostications.
- While concerns like trade wars exist, Demmert sees President Trump's tariff proposals more as negotiation tactics than permanent policies.
- Demmert expects a market turnaround fueled by strong corporate earnings and points out sectors like financials, industrials, healthcare, and utilities as likely beneficiaries.
- He advises investors to consider cyclical sectors for potential growth opportunities amidst the current market volatility.
- Demmert also sees value in defensive sectors like healthcare, suggesting Europe-based biopharmaceutical firm AstraZeneca as an attractive investment.
- The outlook remains positive for the stock market, with expectations for robust Q1 earnings and the potential for a broad-based rally when stocks recover.
- Overall, Demmert emphasizes the importance of focusing on earnings and the economy and highlights the compressed P/E ratio as a favorable investment opportunity.
Insider | 1 Apr, 2025
Xi Jinping Meets Global Business Leaders As China Seeks To Woo Investors
- Chinese President Xi Jinping met with a group of global business leaders in Beijing to boost investor sentiment amid rising tariffs and uncertainty for the economy and international trade.
- The meeting took place at the Great Hall of the People and included representatives from international industrial and business firms, such as FedEx Corp, Standard Chartered PLC, Sanofi SA, AstraZeneca PLC, and ThyssenKrupp AG.
- Xi expressed that the Chinese government will study and consider the views shared by the business representatives, while encouraging them to continue their lines of communication with China.
- The meeting emphasizes China's efforts to position itself as open for business and a supporter of private enterprise, countering protectionist policies and fostering economic growth.
Bloomberg Quint | 28 Mar, 2025
It’s AGM time, season of free sandwiches and protest fireworks
- BP is set to host its annual general meeting (AGM) in Sunbury-on-Thames, facing criticism for its U-turn on green ambitions and poor share performance.
- Major UK companies hold their AGMs in April and May, providing investors a chance to address executives before enjoying free sandwiches.
- The return of Donald Trump to the White House has influenced AGM discussions on diversity, equity, climate goals, and ESG risks.
- Some investors are easing their climate stance, with Aviva Investors and BlackRock making significant changes in line with political shifts.
- Boardroom pay, diversity initiatives, and executive pay packets are key topics at AGMs, with companies like GSK and AstraZeneca facing scrutiny.
- Shareholder rebellions over executive pay, such as against AstraZeneca's CEO Pascal Soriot, have been seen in the past.
- Institutional Shareholder Services highlight the importance of addressing shareholder concerns over variable pay at AGMs.
- Hybrid AGM meetings, both in-person and online, have become more common since the pandemic, contrasting with virtual-only meetings in North America.
- The traditional in-person AGMs continue to offer a compelling spectacle compared to virtual-only meetings.
Guardian | 23 Mar, 2025
Post-Treatment Blood Tests May Guide Future Cancer Treatment Choices
- Recent research from Yale University introduces a tool to detect cancer-derived molecules in post-treatment blood of lung cancer patients, aiding in personalized follow-up therapies.
- Molecular residual disease (MRD) detection reveals tumor DNA fragments in the bloodstream, guiding clinicians on patient remission status and potential relapse risks.
- Dr. Roy Herbst of Yale School of Medicine highlights MRD detection's role in cancer patient monitoring and decision-making for treatment intensification.
- The study, published in Nature Medicine, focuses on osimertinib's efficacy for EGFR-mutated non-small cell lung cancer post-surgery.
- MRD detection offers a personalized approach for treatment decisions post-primary treatment completion, distinguishing high and low-risk patients for tailored interventions.
- Collaborative efforts between Yale and the Guangdong Lung Cancer Institute, supported by AstraZeneca, aim to revolutionize cancer treatment through MRD detection.
- The shift towards personalized cancer care through molecular diagnostics like MRD detection enhances patient outcomes and treatment efficacy.
- Emphasizing precision and customization, MRD detection signals a transformative era in oncology that prioritizes individualized patient care.
- By leveraging advanced molecular techniques, MRD detection can mold future cancer interventions based on patient-specific genetic profiles.
- Yale's breakthrough research underscores the potential of MRD detection to improve cancer care through enhanced monitoring and personalized treatment.
Bioengineer | 17 Mar, 2025
AstraZeneca Pharma India Gets CDSCO Approval To Sell Cancer Treatment Drug
- AstraZeneca Pharma India receives approval from CDSCO (Central Drugs Standard Control Organisation) to sell cancer treatment drug Durvalumab solution.
- The approval is for import, sale, and distribution of Durvalumab solution for the treatment of patients with unresectable hepatocellular carcinoma (uHCC).
- The permission allows AstraZeneca Pharma to market Durvalumab solution for infusion in India, subject to further statutory approvals.
- Shares of AstraZeneca Pharma India closed 2.38% higher following the announcement.
Bloomberg Quint | 3 Mar, 2025
British pharma company GSK pauses diversity work citing Trump orders
- British pharma company GSK has paused diversity activities for UK workers.
- The company claims it is obliged to do so in response to executive orders by Donald Trump.
- GSK has also removed references to 'diversity' from its website.
- The move by GSK contrasts with its British pharma rival AstraZeneca, which has not made any changes to its diversity policies.
Guardian | 1 Mar, 2025
Stock Market Today: All You Need To Know Going Into Trade On Feb. 12
- The Indian equity benchmark indices, NSE Nifty 50 and BSE Sensex, closed lower with the Nifty down 1.32% and Sensex 1.31% lower.
- Asian stocks had a mixed day with Japan's Nikkei 225 up, while South Korea's Kospi and Australia's S&P/ASX 200 remained unchanged. Hang Seng futures declined.
- US stocks fluctuated, bond yields rose after Federal Reserve Chair Jerome Powell reiterated no rush to cut rates. S&P 500 and Dow Jones had little changes.
- Foreign portfolio investors were net sellers of Indian equities, while domestic institutional investors were net buyers.
- The rupee closed stronger against the US dollar on Tuesday.
- Earnings highlights post-market hours included results from companies like Birlasoft, Vodafone Idea, AstraZeneca Pharma India, Berger Paints, IRCTC, Time Technoplast, Technocraft Industries, NBCC (India), and more.
- Stocks to watch included TVS Motor Co., H.G. Infra Engineering, Hatsun Agro Product, Jupiter Wagons, BEML, Bharat Heavy Electricals, and Happy Forgings.
- IPO offerings mentioned were Ajax Engineering and Hexaware Technologies with details on subscription rates.
- Insider trading updates related to Paisalo Digital and GPT Infraprojects were reported, along with bulk deals in Sterling and Wilson Renewable Energy.
- Trading tweaks like price band changes, ex-dividend listings, and stocks moving in and out of short-term ASM framework were observed.
- F&O cues showed Nifty Feb futures down, options data, and securities in the ban period.
Bloomberg Quint | 12 Feb, 2025
AstraZeneca Pharma India Gets Warning Letter From NSE
- AstraZeneca Pharma India received a warning letter from the National Stock Exchange (NSE) for non-compliance with a regulatory norm.
- The company violated the provision that mandates the attendance of at least two independent directors in an audit committee meeting.
- NSE advised AstraZeneca Pharma India to exercise caution, take corrective steps, and avoid recurrence of such lapses.
- The stock of AstraZeneca Pharma India closed 0.81% lower at Rs 7,550 apiece on the NSE.
Bloomberg Quint | 10 Feb, 2025
Union Budget 2025: Cancer medicines and patient assistance programmes come in for reprieve
- Medicines from multinational companies, including Pembrolizumab (MSD Pharma), Lorlatinib (Pfizer), Ribociclib (Novartis), Selumetinib (Astra Zeneca), Teclistamab (Johnson & Johnson), Cetuximab (Merck Specialities), Brentuximab Vedotin (Takeda); Mepolizumab (GSK Pharma), Risdiplam Powder (Roche), Luspatercept (Bristol Myers Squibb) are among the 37 listed to get Basic Customs Duty exemptions, provided they are given free.
- Additionally, the budget proposes to add 13 new patient assistance programs for supplying medicines free of cost to patients.
- 36 lifesaving drugs and medicines will be added to the list of medicines fully exempted from Basic Customs Duty (BCD), and 6 lifesaving medicines will be eligible for concessional customs duty of 5 percent.
- The budget also plans to establish 200 daycare cancer centers in all district hospitals in the next three years.
HinduBusinessLine | 1 Feb, 2025
Jobs Reports Due for Next Week
- The report contains jobs numbers from the US and Canada along with their featured earnings for the upcoming week.
- Monday will see the announcement of economic data regarding the S&P's final US manufacturing PMI, Construction spending, ISM manufacturing and Auto Sales for January.
- On Tuesday, reports will be published announcing job openings data and factory orders for December in the US, as well as the Canadian international merchandise trade for December.
- Wednesday will bring information about ADP employment, US trade deficit, the S&P final US services PMI and ISM services.
- Thursday will see the release of the US initial jobless claims, US productivity for Q4 along with featured earnings for companies including Amazon.com Inc., Eli Lilly And Co, and AstraZeneca PLC.
- Friday will announce the US employment report for January, wholesale inventories and Consumer sentiment, along with earnings from Southern Copper Corp, Fortive Corporation and Kimco Realty Corporation.
- This week's earnings reports include Palantir Technologies, NXP Semiconductors NV, IDEXX Laboratories, Char Technologies, LithiumBank Resources Corp, and TMX Group Limited for Monday.
- On Tuesday, earnings for Alphabet Inc, Toyota Motor Corporation, and Merck & Co Inc will be announced.
- Wednesday's earnings reports include those of NovoNordisk, Alibaba Group Holding Ltd and Walt Disney Co.
- Thursday's featured earnings reports include BCE Inc., Bombardier Inc., Canada Goose Holdings Inc, Colliers International Group Inc., Constellation Software Inc and Lightspeed Commerce Inc.
- Friday's earnings reports include ARC Resources, CAE Inc. Unlimited and Canopy Growth Corporation.
Baystreet | 1 Feb, 2025
Powered by
AstraZeneca Offices
Compare AstraZeneca with
Sanofi
4.2
Unichem Laboratories
3.8
Piramal Pharma
4.0
Strides Pharma
3.9
Jubilant Pharmova
3.8
Natco Pharma
4.0
Shilpa Medicare
3.4
Flamingo Pharmaceuticals
3.2
Novartis Healthcare
4.1
Marksans Pharma
3.2
Concord Biotech
3.7
Bliss Gvs Pharma
4.1
Gufic Biosciences
3.5
Caplin Point Laboratories
3.7
Sami-Sabinsa Group
2.9
Kopran
3.6
SAVA Healthcare
3.7
Kwality Pharmaceuticals
3.8
SMS Pharmaceuticals
3.5
SeQuent Scientific
3.7
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to AstraZeneca
Granules India
Manufacturing, Pharma
3.8
• 1.2k reviews
Sanofi
Biotech & Life sciences, Manufacturing, Analytics & KPO, Pharma
4.2
• 1.2k reviews
Unichem Laboratories
Pharma
3.8
• 1.1k reviews
Piramal Pharma
Biotech & Life sciences, Pharma
4.0
• 1k reviews
Strides Pharma
Pharma
3.9
• 917 reviews
Jubilant Pharmova
Clinical Research, Pharma
3.8
• 871 reviews
Natco Pharma
Manufacturing, Pharma
4.0
• 760 reviews
Shilpa Medicare
Pharma
3.4
• 712 reviews
Flamingo Pharmaceuticals
Manufacturing, Pharma
3.2
• 399 reviews
Novartis Healthcare
Manufacturing, Analytics & KPO, Pharma
4.1
• 356 reviews
AstraZeneca FAQs
When was AstraZeneca founded?
AstraZeneca was founded in 1999. The company has been operating for 26 years primarily in the Pharma sector.
Where is the AstraZeneca headquarters located?
AstraZeneca is headquartered in Cambridge, Cambridgeshire.
How many employees does AstraZeneca have in India?
AstraZeneca currently has more than 900+ employees in India. Engineering - Software & QA department appears to have the highest employee count in AstraZeneca based on the number of reviews submitted on AmbitionBox.
Does AstraZeneca have good work-life balance?
AstraZeneca has a work-life balance rating of 4.1 out of 5 based on 800+ employee reviews on AmbitionBox. 80% employees rated AstraZeneca 4 or above on work-life balance. This rating reflects the company's efforts to help employees maintain a healthy balance between their personal and professional lives. We encourage you to read AstraZeneca work-life balance reviews for more details
Is AstraZeneca good for career growth?
Career growth at AstraZeneca is rated as moderate, with a promotions and appraisal rating of 3.4. 20% employees rated AstraZeneca 3 or below, while 80% employees rated it 4 or above on promotions/appraisal. This rating suggests that while some employees view growth opportunities favorably, there is scope for improvement based on employee feedback. We recommend reading AstraZeneca promotions/appraisals reviews for more detailed insights.
What are the pros of working in AstraZeneca?
Working at AstraZeneca offers several advantages that make it an appealing place for employees. The company is highly rated for work life balance, company culture and salary & benefits, based on 800+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
